Phaseline

Companies › Iovance Biotherapeutics

Iovance Biotherapeutics: clinical trials, targets and expected readouts

5 active drug programs in 11 registered trials: 6 Phase 1, 5 Phase 2; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lifileucel
Tumor-infiltrating lymphocytes (TIL) autologous cell therapy
–Phase 2Melanoma (Skin Cancer); Endometrial Cancer; Sarcoma; Locally Advanced Melanoma …Dec 2027
LN-145
Autologous tumor infiltrating lymphocytes (TIL) expanded ex vivo, administered after lymph
–Phase 2Metastatic Non Small Cell Lung Cancer; Cutaneous Squamous Cell CarcinomaDec 2030
IOV-4001
Autologous tumor infiltrating lymphocyte (TIL) therapy
–Phase 1Unresectable MelanomaSep 2027
IOV-3001
Modified interleukin-2 fusion protein
IL2Phase 1Unresectable MelanomaJun 2032
LN-145/LN-144
Autologous tumor-infiltrating lymphocytes (TIL) therapy
–Phase 1Soft Tissue Sarcoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06566092LN-145/LN-144Phase 1Soft Tissue SarcomaOncologyJun 2026
NCT05176470LifileucelPhase 1Locally Advanced MelanomaOncologyDec 2026
NCT05607095LifileucelPhase 1Uveal MelanomaOncologyMay 2027
NCT05361174IOV-4001Phase 1Unresectable MelanomaOncologySep 2027
NCT05640193LifileucelPhase 1Metastatic MelanomaOncologyNov 2027
NCT07288203LifileucelPhase 2Melanoma (Skin Cancer)OncologyDec 2027
NCT06481592LifileucelPhase 2Endometrial CancerOncologyMay 2028
NCT07288073LN-145Phase 2Cutaneous Squamous Cell CarcinomaOncologySep 2028
NCT04614103LN-145Phase 2Metastatic Non Small Cell Lung CancerOncologyDec 2030
NCT06940739IOV-3001Phase 1Unresectable MelanomaOncologyJun 2032
NCT07741877LifileucelPhase 2SarcomaOncologySep 2033

From the company's SEC filings

Cash and short-term investments of $376m on 2026-09-30; operating cash outflow about $184m a year; runway about 24 months at that burn, to Oct 2028; 3 of 5 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

IL2 (1)

Companies with the same targets

Innovent Biologics (Suzhou) AstraZeneca Medicenna Therapeutics Coya Therapeutics Synthekine Nektar Therapeutics HCW Biologics Asher Biotherapeutics Regeneron Pharmaceuticals Salspera

Companies built like this

Salspera Shanghai Juncell Therapeutics Grit Biotechnology Binhui Biopharmaceutical Orca Biosystems

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.